179022-43-6 Usage
Description
Methyl 8-azabicyclo[3.2.1]octane-3-carboxylate is a bicyclic chemical compound with the molecular formula C10H15NO2. It features a nitrogen heteroatom and a carboxylic acid ester functional group, making it a versatile building block in organic synthesis and drug discovery research. Its unique structure and reactivity contribute to its value in the development of novel pharmaceuticals and bioactive compounds.
Uses
Used in Pharmaceutical Industry:
Methyl 8-azabicyclo[3.2.1]octane-3-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals and bioactive compounds. Its unique structure and reactivity enable the development of novel drug molecules with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, Methyl 8-azabicyclo[3.2.1]octane-3-carboxylate serves as a valuable building block for the creation of complex organic molecules. Its presence in the synthesis process can lead to the formation of new compounds with diverse applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 179022-43-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,0,2 and 2 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 179022-43:
(8*1)+(7*7)+(6*9)+(5*0)+(4*2)+(3*2)+(2*4)+(1*3)=136
136 % 10 = 6
So 179022-43-6 is a valid CAS Registry Number.
179022-43-6Relevant articles and documents
SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS
-
Paragraph 0347, (2017/05/27)
There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.
